Christoph Klade
12 Papers
25 Citations
Christoph Klade is an academic researcher. The author has contributed to research in topics: Polycythemia vera & Pegylated interferon. The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.
Heinz Gisslinger,Oleh Zagrijtschuk,Veronika Buxhofer-Ausch,Josef Thaler,Ernst Schloegl,Guenther Gastl,Dominik Wolf,Robert Kralovics,Robert Kralovics,Bettina Gisslinger,Karin Strecker,Alexander Egle,Thomas Melchardt,Sonja Burgstaller,Ella Willenbacher,Martin Schalling,Nicole C.C. Them,Pavla Kadlecová,Christoph Klade,Richard Greil +19 more
TL;DR: It is suggested that already low levels of ropeginterferon alfa-2b are sufficient to induce significant hematologic and molecular responses and support the development of the drug in a randomized phase 3 clinical trial.
167
Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.
Martin Unger,Andrea Morelli,Mervyn Singer,Peter Radermacher,Sebastian Rehberg,Helmut Trimmel,Michael Joannidis,Gottfried Heinz,Vladimir Cerny,Pavel Dostál,Christian Siebers,Fabio Guarracino,Francesca Pratesi,Gianni Biancofiore,Massimo Girardis,Pavla Kadlecová,Olivier Bouvet,Michael Zörer,Barbara Grohmann-Izay,Kurt Krejcy,Christoph Klade,G. Krumpl +21 more
TL;DR: This multicenter study is to demonstrate that administration of the highly beta1-selective and ultrashort-acting beta blocker landiolol in patients with septic shock and persistent tachycardia is effective in reducing and maintaining HR without increasing vasopressor requirements.
Efficacy and Safety Of AOP2014/P1101, a Novel, Investigational Mono-Pegylated Proline-Interferon Alpha-2b, In Patients With Polycythemia Vera (PV): Update On 51 Patients From The Ongoing Phase I/II Peginvera Study
Heinz Gisslinger,Veronika Buxhofer-Ausch,Josef Thaler,Ernst Schloegl,Guenther Gastl,Dominik Wolf,Robert Kralovics,Bettina Gisslinger,Daniel Lechner,Karin Strecker,Alexander Egle,Thomas Melchardt,Sonja Burgstaller,Ella Willenbacher,Michael Zoerer,Oleh Zahriychuk,Christoph Klade,Richard Greil +17 more
TL;DR: Long term efficacy and safety data are being collected in the follow-up extension stage of the study, after the maximum tolerated dose (MTD) of AOP2014, administered subcutaneously every 14 days, has been defined earlier.
9
AOP2014, a Novel Peg-Proline-Interferon Alpha-2b with Improved Pharmacokinetic Properties, Is Safe and Well Tolerated and Shows Promising Efficacy in Patients with Polycythemia Vera (PV)
Heinz Gisslinger,Robert Kralovics,Bettina Gisslinger,Daniel Lechner,Veronika Buxhofer-Ausch,Karin Strecker,Guenther Gastl,Ella Willenbacher,Richard Greil,Alexander Egle,Thomas Melchardt,Sonja Burgstaller,Ernst Schloegl,Franz-Josef Tarmann,Michael Zoerer,Christoph Klade,Oleh Zahriychuk,Josef Thaler +17 more
TL;DR: The maximum tolerated dose (MTD), long term safety and efficacy of AOP2014, administered subcutaneously every 14 days, are the main objectives of the study.
6
Patent
Targeted cancer immune therapy
Thomas Felzmann,Christoph Klade,Andreas Obwaller,Oleh Zahriychuk +3 more
- 02 Apr 2014
TL;DR: In this article, the combination of an active cancer immune medicament and a passive immune-therapeutic drug, wherein the passive immune therapeutic drug is a monoclonal antibody (MAB) specific for a tumour-associated antigen (TAA), was described.
6